Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22531723 | 0.89 | GRM5 (0.38) | GRM5CYP2A6 | |
| SCHEMBL31014678 | 0.81 | GRM5 (0.34) | GRM5CYP2A6 | |
| SCHEMBL14903886 | 0.80 | GRM5 (0.51) | GRM5HCAR2CYP2A6ATM | |
| SCHEMBL6553370 | 0.79 | FFAR1 (0.34) | GRM5 | |
| SCHEMBL503406 | 0.79 | GRM5 (0.33) | GRM5CYP2A6 | |
| SCHEMBL12938274 | 0.79 | GRM5 (0.39) | GRM5HCAR2 | |
| SCHEMBL1476913 | 0.79 | GRM5 (0.40) | GRM5HCAR2 | |
| SCHEMBL503839 | 0.79 | KDM4E (0.34) | GRM5CYP2A6 | |
| SCHEMBL1476678 | 0.79 | RAF1 (0.38) | GRM5 | |
| SCHEMBL29434830 | 0.79 | GRM5 (0.40) | GRM5HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-16 | — | — | US | disclosed |
| CN-116546984-A | Selective agonists of 5-HT2A receptors and methods of use thereof | 耶鲁大学 | 2023-08-04 | — | — | CN | disclosed |
| EP-4216949-A1 | SELECTIVE AGONISTS OF 5-HT2A RECEPTOR AND METHODS OF USE | Yale University (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2018011094-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2018-01-18 | — | — | WO | disclosed |
| US-8710055-B2 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710055-B2 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| EP-2655326-A1 | 4- (HETERO) ARYL - ETHYNYL - OCTAHYDRO - INDOLE - 1 - CARBOXYLIC ACID ESTERS | Novartis AG (CH) | 2013-10-30 | — | — | EP | disclosed |
| US-20130274294-A1 | 4-(Hetero)Aryl-Ethynyl-Octahydro-Indole-1-Esters | NOVARTIS PHARMA AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20120322803-A1 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| WO-2012084873-A1 | 4- (HETERO) ARYL - ETHYNYL - OCTAHYDRO - INDOLE - 1 - CARBOXYLIC ACID ESTERS | NOVARTIS AG (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | HTR2A, HTR2C, HTR2B | GRM5 39/4885HCAR2 68/4885CYP2A6 1214/4885 |
| US-20120322803-A1 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | CDK2, TNNI3K, CDK1 | GRM5 2634/4885HCAR2 4026/4885CYP2A6 4180/4885 |
| US-20130274294-A1 | 4-(Hetero)Aryl-Ethynyl-Octahydro-Indole-1-Esters | IDO1, TPH1, IDO2 | GRM5 775/4885HCAR2 239/4885CYP2A6 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.